白介素-17 抑制剂在轴性脊柱关节炎中的应用：现状与未来展望。
IL-17 inhibition in axial spondyloarthritis: current and future perspectives.
机构信息
a Division of Rheumatology, Department of Internal Medicine , Ankara University Faculty of Medicine , Ankara , Turkey.
b Department of Gastroenterology , Infectiology and Rheumatology, Campus Benjamin Franklin, Charité - Universitätsmedizin , Berlin , Germany.
出版信息
Expert Opin Biol Ther. 2019 Jul;19(7):631-641. doi: 10.1080/14712598.2019.1605352. Epub 2019 Apr 19.
INTRODUCTION
Interleukin (IL)-17 is a proinflammatory cytokine considered to play a significant role in the immunopathogenesis of ankylosing spondylitis (AS)/axial spondyloarthritis (axSpA) as well as of other spondyloarthritides. There is a number of substances targeting IL-17, which are at different stages of development in the axSpA indication.
AREAS COVERED
This review summarizes the current evidence on the role of IL-17 in the pathophysiology of axSpA and provided a comprehensive review of clinical and radiographic outcomes as well as of safety data from studies with IL-17A inhibitors secukinumab and ixekizumab. Ongoing studies on other IL-17 inhibitors (bimekizumab, brodalumab and BCD-085) that are being developed are also summarized.
EXPERT OPINION
The development of the IL-17 inhibitors has expanded AS treatment with effective options and confirmed the pathophysiological role of IL-17 in axSpA. IL-17 inhibition showed sufficient efficacy against signs and symptoms of the disease even after the failure of tumor necrosis factor inhibitors, being at the same time reasonably safe.
简介
白细胞介素（IL）-17 被认为是一种促炎细胞因子，在强直性脊柱炎（AS）/中轴型脊柱关节炎（axSpA）以及其他脊柱关节炎的免疫发病机制中起重要作用。有许多针对 IL-17 的物质，它们在 axSpA 适应证中处于不同的开发阶段。
涵盖领域
本文综述了 IL-17 在 axSpA 病理生理学中的作用的现有证据，并对 secukinumab 和 ixekizumab 等 IL-17A 抑制剂研究中的临床和放射学结局以及安全性数据进行了全面综述。还总结了正在开发的其他 IL-17 抑制剂（bimekizumab、brodalumab 和 BCD-085）的研究进展。
专家意见
IL-17 抑制剂的开发为 AS 治疗提供了有效的选择，并证实了 IL-17 在 axSpA 中的病理生理作用。IL-17 抑制在肿瘤坏死因子抑制剂失效后对疾病的体征和症状也显示出足够的疗效，同时具有合理的安全性。
Zotero 插件